secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adverum Biotechnologies, Inc. (—)
CIK:        0001501756
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001193125-24-159134
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Adverum appoints Rabia Ozden as CMO, Szilard Kiss to board, effective June 10
-----------------------------------------------------------------------------

- Rabia Gurses Ozden, M.D. appointed Chief Medical Officer effective June 10, 2024.
- Ozden resigned from the Board and R&D Committee effective same date.
- Szilard Kiss, M.D. appointed as Class III director; expected to join R&D Committee.
- Kiss is a retina specialist, professor at Weill Cornell, and CMO of Blue Gen Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/d849862d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-159134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer